Browse by author
Lookup NU author(s): Dr Luke Milross, Chelsea Griffiths, Professor Andrew FisherORCiD
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
© 2021 by the authors.Lung transplantation offers a lifesaving therapy for patients with end-stage lung disease but its availability is presently limited by low organ utilization rates with donor lungs frequently excluded due to unsuitability at assessment. When transplantation does occur, recipients are then vulnerable to primary graft dysfunction (PGD), multitudinous short-term complications, and chronic lung allograft dysfunction. The decision whether to use donor lungs is made rapidly and subjectively with limited information and means many lungs that might have been suitable are lost to the transplant pathway. Compared to static cold storage (SCS), ex vivo lung perfusion (EVLP) offers clinicians unrivalled opportunity for rigorous objective assessment of donor lungs in conditions replicating normal physiology, thus allowing for better informed decision-making in suitability assessments. EVLP additionally offers a platform for the delivery of intravascular or intrabronchial therapies to metabolically active tissue aiming to treat existing lung injuries. In the future, EVLP may be employed to provide a pre-transplant environment optimized to prevent negative outcomes such as primary graft dysfunction (PGD) or rejection post-transplant.
Author(s): Milross L, Griffiths C, Fisher AJ
Publication type: Review
Publication status: Published
Journal: Transplantology
Year: 2021
Volume: 2
Issue: 4
Pages: 387-395
Print publication date: 01/12/2021
Online publication date: 27/09/2021
Acceptance date: 24/09/2021
ISSN (electronic): 2673-3943
Publisher: MDPI
URL: https://doi.org/10.3390/transplantology2040037
DOI: 10.3390/transplantology2040037
